Stay updated with breaking news from Nasdaq atha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 717,600 shares, an increase of 39.6% from the January 15th total of 513,900 shares. Based on an average daily volume of 331,300 shares, the short-interest ratio […] ....
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) CEO Mark James Litton sold 4,820 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $2.91, for a total value of $14,026.20. Following the sale, the chief executive officer now directly owns 144,397 […] ....
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) Director Perceptive Advisors Llc purchased 32,134 shares of the stock in a transaction on Wednesday, December 27th. The shares were purchased at an average cost of $2.28 per share, with a total value of $73,265.52. Following the transaction, the director now owns 4,829,412 shares of the company’s […] ....
Athira Pharma (NASDAQ:ATHA – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Earnings & Valuation This table compares Athira Pharma and […] ....
Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 741,900 shares, a decline of 7.6% from the September 15th total of 803,300 shares. Based on an average trading volume of 145,700 shares, […] ....